Singapore Manufacturing Growth Slows to 3.4% in September as Biomedical Output Plunges 32.8%

Inside Singapore's September Output Slowdown: Pharma Collapse, Chip Equipment Boom

Singapore's manufacturing sector grew in September, but far more slowly than a month earlier. Factory output rose 3.4% compared with September 2025, according to preliminary data from the Singapore Economic Development Board — a steep deceleration from the 15.4% year-over-year expansion recorded in August. The headline number, however, conceals two very different stories running through the city-state's industrial base.

The drag came almost entirely from biomedical manufacturing, which contracted 32.8% year over year. Within that cluster, pharmaceuticals output collapsed 65.9% because manufacturers were producing a different mix of active pharmaceutical ingredients than a year earlier — a composition shift rather than a demand collapse. Medical technology output also slipped 1.7% on softer export demand. Strip out the biomedical cluster entirely and Singapore's factory output actually rose 9.0% in September.

Most other clusters expanded. Precision engineering was the standout, surging 31% on the back of higher production of semiconductor equipment, precision metal products and industrial rubber goods. Transport engineering grew 10.6%, helped by aircraft-parts output and sustained maintenance, repair and overhaul work for commercial airlines, which partly offset weaker marine and offshore engineering activity. Electronics rose 5.7%, with every segment except other electronic modules and components posting growth amid robust AI-related demand. General manufacturing industries added 4%, supported by food, beverage and tobacco production and commercial printing.

Chemicals was the other soft spot, declining 4.6% as petrochemicals fell 24.3% on softer demand and feedstock supply disruptions, though growth in specialties and petroleum partly cushioned the drop. For the first nine months of 2026, total manufacturing output is up 9.8% year over year, and up 13.4% excluding biomedical. Electronics has grown 24.6% over that period and precision engineering 18% — a reminder that the underlying industrial momentum remains tied to the semiconductor and AI supply chain.

Why Singapore's Factory Data Is Two Stories Wearing One Number

Why the Headline Number Misleads

The gap between 3.4% headline growth and 9.0% growth excluding biomedical manufacturing is the single most important fact in this release. Singapore's biomedical cluster is dominated by a small number of high-value pharmaceutical plants whose output swings with product mix and batch scheduling rather than with the business cycle. A 65.9% fall in pharmaceuticals output driven by a different mix of active pharmaceutical ingredients is a compositional effect, not evidence of collapsing end-demand. Analysts and policymakers reading this release will focus on the ex-biomedical figure, which shows the export-oriented manufacturing engine still running well above trend.

Precision Engineering and Electronics Carry the Cycle

The 31% surge in precision engineering — explicitly attributed to semiconductor equipment production — alongside 5.7% electronics growth on AI-related demand confirms that Singapore remains a direct beneficiary of the global build-out in AI compute capacity. The nine-month figures reinforce the point: electronics up 24.6% and precision engineering up 18% year over year. For context, this pattern mirrors the broader regional dynamic in which semiconductor capital equipment and advanced packaging have become the fastest-growing segments of Asia's electronics supply chain, while legacy components lag. The article notes that other electronic modules and components was the only electronics segment to decline, consistent with that bifurcation.

Transport Engineering's Quiet Strength

Transport engineering's 10.6% growth deserves attention because it is broad-based in a way the headline does not capture. Aerospace output rose on higher aircraft-parts production and sustained maintenance, repair and overhaul work from commercial airlines — a services-linked revenue stream that is less cyclical than new-build manufacturing. That strength partly offset weaker marine and offshore engineering, a segment still working through the long tail of the offshore energy investment cycle. For Singapore's aerospace cluster, sustained MRO demand from airlines is a durable positive.

Chemicals: The Second Soft Spot

Chemicals fell 4.6%, with petrochemicals down 24.3% on softer demand and feedstock supply disruptions. The mention of feedstock disruptions points to supply-side constraints rather than purely weak demand, and the partial offset from specialties and petroleum suggests the decline is segment-specific. Still, a nearly one-quarter drop in petrochemicals output is a meaningful drag that, combined with biomedical, explains why the headline decelerated so sharply.

What to Watch From Here

The medium-term picture hinges on three things: whether pharmaceutical output mix normalizes in coming months (which would mechanically lift the headline), whether AI-related semiconductor equipment demand sustains precision engineering's momentum, and whether petrochemical feedstock disruptions ease. The nine-month trend of 9.8% total growth and 13.4% ex-biomedical growth suggests the underlying trajectory remains solid, but the September print is a reminder that headline volatility in Singapore's manufacturing data is largely a biomedical story.

What Singapore's Split Manufacturing Data Means for Suppliers, Investors and Planners

Singapore's September manufacturing data is two stories in one number: a volatile pharmaceutical mix effect dragging the headline to 3.4%, and a genuinely strong 9.0% ex-biomedical underlying engine powered by semiconductor equipment and AI demand.

For executives, investors and planners exposed to Singapore's industrial base, the practical implications are specific:

• Discount the headline, track the ex-biomedical series. The 9.0% September figure and the 13.4% nine-month ex-biomedical growth rate are the better read on underlying momentum; the 65.9% pharma decline reflects product mix, not demand destruction.
• Semiconductor equipment and precision engineering remain the growth engine. With precision engineering up 31% in September and 18% over nine months, suppliers and service providers tied to semiconductor capital equipment should plan capacity around continued demand, while watching for any shift in AI-related order books.
• Aerospace MRO is a durable revenue stream. Transport engineering's 10.6% growth was supported by sustained maintenance, repair and overhaul work from commercial airlines — a segment less exposed to new-build cyclicality than marine and offshore engineering, which remained weak.
• Watch petrochemicals for feedstock normalization. The 24.3% petrochemicals decline was attributed partly to feedstock supply disruptions; easing of those constraints, plus continued specialties and petroleum growth, would stabilize the chemicals cluster.
• Expect headline volatility to persist. Given the concentration of pharmaceutical output in a few plants, monthly headline swings driven by product mix should be anticipated rather than read as turning points.

Metrics worth watching: the EDB's next monthly manufacturing release for any pharma mix normalization; electronics and precision engineering cluster growth rates as a proxy for AI-related demand; petrochemicals output for feedstock supply recovery; and the cumulative ex-biomedical growth rate as the cleanest gauge of Singapore's industrial momentum.